Tamarin alpha-interferon is active in mouse liver upon intramuscular gene delivery

Journal of Gene Medicine

Volumn 3, Issue 4, 2001, Pages 394-402

  Aurisicchio, Luigi ^a   Ceccacci, Alessandra ^a   La Monica, Nicola ^a   Palombo, Fabio ^a   Traboni, Cinzia ^a  

^a IRBM   (Italy)

Author keywords

Animal model; Electro gene transfer; Hepatitis; Interferon; Liver

Indexed keywords

ANIMALIA; HEPATITIS C VIRUS; HEPATITIS GB VIRUS B; PAN (APE); PRIMATES; SAGUINUS IMPERATOR;

ALPHA INTERFERON; ALPHA2A INTERFERON; COMPLEMENTARY DNA; PRIMER DNA;

5' UNTRANSLATED REGION; ANIMAL; ANTHROPOIDEA; ARTICLE; CELL CULTURE; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; HELA CELL; HUMAN; L CELL; LIVER; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHYLOGENY; PHYSIOLOGY; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; TRANSGENIC MOUSE;

5' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; CLONING, MOLECULAR; DNA PRIMERS; DNA, COMPLEMENTARY; HELA CELLS; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; L CELLS (CELL LINE); LIVER; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; PHYLOGENY; SAGUINUS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, NUCLEIC ACID; TUMOR CELLS, CULTURED;

EID: 0035404420     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.196     Document Type: Article

References (40)

1. Rice CM. Flaviviridae: the viruses and their replication. In Virology (3rd edn), Fields BN, Knipe DM, Howley PM (eds). Raven Press: New York, NY, 1996.
2. De Francesco R. Molecular virology of the hepatitis C virus. J Hepatol 1999; 31 (Suppl. 1): 47-53.
3. World Health Organization (WHO). Global surveillance and control of hepatitis C. J Viral Hepat 1999; 6: 35-14.
4. World Health Organization (WHO). Hepatitis C-global prevalence (update). Wkly Epidemiol Rec 2000; 75: 18-19.
5. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30: 595-601.
6. Simons JN, Pilot-Matias TJ, Leary TP, et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci U S A 1995; 92: 3401-3405.
7. Muerhoff AS, Leary TP, Simons JN, et al. Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis. J Virol 1995; 69: 5621-5630.
8. Scarselli E, Urbani A, Sbardellati A, Tomei L, De Francesco R, Traboni C. GB virus B and hepatitis C virus NS3 serine proteases share substrate specificity. J Virol 1997; 71: 4985-4989.
9. Sbardellati A, Scarselli E, Tomei L, Kekulé AS, Traboni C. Identification of a novel sequence at the 3′-end of GB virus B (GBV-B) genome. J Virol 1999; 73: 10546-0550.
10. Zhong W, Ingravallo P, Wright-Minogue J, et al. Nucleoside triphosphatase and RNA helicase activities associated with GB virus B nonstructural protein 3. Virology 1999; 261: 216-226.
11. Butkiewicz N, Yao N, Zhong W, et al. Virus-specific cofactor requirement and chimeric hepatitis C Virus/GB virus B nonstructural protein 3. J Virol 2000; 74: 4291-4301.
12. Grace K, Gartland M, Karayiannis P, McGarvey MJ, Clarke B. The 5′ untranslated region of GB virus B shows functional similarity to the internal ribosome entry site of hepatitis C virus. J Gen Virol 1999; 80: 2337-2341.
13. Rijnbrand R, Abell G, Lemon SM. Mutational analysis of the GB virus B internal ribosome entry site. J Virol 2000; 74: 773-783.
14. Bukh J, Apgar CL, Yanagi M. Toward a surrogate model for hepatitis C virus: an infectious molecular clone of the GB virus-B hepatitis agent. Virology 1999; 262: 470-478.
15. Zhong W, Ingravallo P, Wright-Minogue J, et al. RNA-dependent RNA polymerase activity encoded by GB virus-B non-structural protein 5B. J Viral Hepat 2000; 7: 335-342.
16. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
17. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-1499.
18. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258.
19. Gresser I. Biological effect of interferons. Soc Invest Dermatol 1990; 95: S66.
20. Fleischmann CM, Fleischmann Jr WR. Differential antiproliferative activities of IFNs alpha, beta and gamma: kinetics of establishment of their antiproliferative effects and the rapid development of resistance to IFNs alpha and beta. J Biol Regul Homeost Agents 1988; 2: 173-185.
21. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995; 103: 161-179.
22. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 1996; 17: 369-372.
23. Darnell Jr JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
24. David M. Transcription factors in interferon signaling. Pharmacol Ther 1995; 65: 149-161.
25. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998; 95: 15623-15628.
26. Rice AP, Duncan R, Hershey JW, Kerr IM. Double-stranded RNA-dependent protein kinase and 2-5A system are both activated in interferon-treated, encephalomyocarditis virus-infected HeLa cells. J Virol 1985; 54: 894-898.
27. Karasu Z, Gurakar A, Emmett C, et al. Utilizing daily interferon (alpha 2b) and ribavirin combination therapy in chronic hepatitis C: a preliminary report. J Okla State Med Assoc 1999; 92: 573-577.
28. Aurisicchio L, Delmastro P, Salucci V, et al. Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis. J Virol 2000; 74: 4816-4823.
29. Sambrook JE, Maniatis T, Fritsch F. Molecular Cloning: A Laboratory Manual (2nd edn). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1989.
30. Montgomery DL, Shiver JW, Leander KR, et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 1993; 12: 777-783.
31. Armstrong JA. Cytopathic effect inhibition assay for interferon: microculture plate assay. Methods Enzymol 1981; 78: 381-387.
32. Rizzuto G, Cappelletti M, Maione D, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci USA 1999; 96: 6417-6422.
33. Beames B, Chavez D, Guerra B, Notvall L, Brasky KM, Lanford RE. Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus. J Virol 2000; 74: 11764-11772.
34. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999; 6: 508-514.
35. Brunda MJ, Rosenbaum D. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res 1984; 44: 597-601.
36. Orlic D, Gill R, Feldschuh R, Quaini F, Malice A, Sandoval C. Molecular mechanism for the inhibitory action of interferon on hematopoiesis. Ann N Y Acad Sci 1989; 554: 36-48.
37. Rosenthal GJ, Stranahan RPD, Thompson M, et al. Organ-specific hematopoietic changes induced by a recombinant human interferon-alpha in mice. Fund Appl Toxicol 1990; 14: 666-675.
38. Horton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci U S A 1999; 96: 1553-1558.
39. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987; 56: 727-777.
40. Gloff CA, Benet LZ. Pharmacokinetics and protein therapeutics. Adv Drug Deliv Rev 1990; 4: 359-386.